GCG and diabetes mellitus: Glucagon-like peptide-1 (GLP-1) receptor agonists are a relatively new class of incretin-based agents for the treatment of type 2 diabetes mellitus that lower blood glucose [1, 2], reduce body weight [3], and possibly reduce cardiovascular risk compared to placebo [4, 5].